887411-85-0

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-(TETRAHYDROFURAN-2-YL)-3-OXOPROPANOATE is used as a building block for the synthesis of various pharmaceuticals and organic compounds, contributing to the development of new drugs and medicinal products.
Used in Flavor and Fragrance Industry:
ETHYL 3-(TETRAHYDROFURAN-2-YL)-3-OXOPROPANOATE is used as a flavor and fragrance ingredient in the food and beverage industry, enhancing the sensory experience of products with its strong fruity odor.
Used in Chemical Production:
ETHYL 3-(TETRAHYDROFURAN-2-YL)-3-OXOPROPANOATE is used as an intermediate in the production of various esters, which are essential in the manufacturing of plastics, resins, and adhesives, contributing to the versatility and functionality of these materials.
Safety Precautions:
ETHYL 3-(TETRAHYDROFURAN-2-YL)-3-OXOPROPANOATE is generally considered safe for use in the aforementioned applications, but it should be handled with care and in accordance with proper safety precautions to ensure the well-being of workers and the environment.

InChI:InChI=1/C9H14O4/c1-2-12-9(11)6-7(10)8-4-3-5-13-8/h8H,2-6H2,1H3

Upstream product

• 16874-34-3 ethyl tetrahydrofurancarboxylate 
• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 16874-33-2 tetrahydro-2-furancarboxylic acid 
• 6148-64-7 ethyl potassium malonate 
• 37517-78-5 magnesium bis(3-ethoxy-3-oxopropanoate) 
• 1071-46-1 hydrogen ethyl malonate 
• 148151-47-7 (2R)-tetrahydrofuran-2-carboxylic acid chloride 

Downstream Products

• 1361236-04-5 (+/-)-1-methyl-2-phenyl-5-(tetrahydrofuran-2-yl)-1H-pyrazol-3(2H)-one 

Relevant academic research and scientific papers

PYRAZOLONE DERIVATIVE HAVING CYCLIC SIDE CHAIN

PROBLEM TO BE SOLVED: To provide a compound that has excellent inhibitory action on ATPase activity of TIP48/TIP49 complex and is therefore useful for the treatment of tumor, or a pharmacologically acceptable salt thereof. SOLUTION: The present invention provides a compound having a structure represented by general formula (I), its pharmacologically acceptable salt, or a pharmaceutical composition comprising the compound (where R1, R2, R3, R4, R5, R6, R7, W, and Z are as defined in the specifications). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type i inhibitors and in vivo testing in diet-induced obese mice

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been widely considered by the pharmaceutical industry as a target to treat metabolic syndrome in type II diabetics. We hypothesized that central nervous system (CNS) penetration might be required to see efficacy. Starting from a previously reported pyrimidine compound, we removed hydrogen-bond donors to yield 3, which had modest CNS penetration. More significant progress was achieved by changing the core to give 40, which combines good potency and CNS penetration. Compound 40 was dosed to diet-induced obese (DIO) mice and gave excellent target engagement in the liver and high free exposures of drug, both peripherally and in the CNS. However, no body weight reduction or effects on glucose or insulin were observed in this model. Similar data were obtained with a structurally diverse thiazole compound 51. This work casts doubt on the hypothesis that localized tissue modulation of 11β-HSD1 activity alleviates metabolic syndrome.

2 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS

2-Amino-pyrimidine derivatives of formula I, wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine receptor H4antagonists.